SUPRAX 200 MG
CEFIXIME : 200 MG · DIN 00868973 · SANOFI-AVENTIS CANADA INC
Health Canada status: CANCELLED POST MARKET
What is SUPRAX?
SUPRAX 200 MG contains CEFIXIME : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 00868973, held by SANOFI-AVENTIS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 05-May-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00868973 |
|---|---|
| Brand name | SUPRAX |
| Generic / active ingredient | CEFIXIME : 200 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 200 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01DD08 CEFIXIME |
| AHFS class | 08:12.06.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 05-May-2006 |
| Original market date | 1990-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code J01DD08 CEFIXIME. 4 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-CEFIXIME | 100 MG / 5 ML | POWDER FOR SUSPENSION | AURO PHARMA INC | MARKETED | DIN 02468689 |
| AURO-CEFIXIME | 400 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02432773 |
| SUPRAX | 100 MG / 5 ML | POWDER FOR SUSPENSION | ODAN LABORATORIES LTD | MARKETED | DIN 00868965 |
| SUPRAX | 400 MG | TABLET | ODAN LABORATORIES LTD | MARKETED | DIN 00868981 |
| SUPRAX | 100 MG / 5 ML | POWDER FOR SOLUTION | AVENTIS PHARMA INC | CANCELLED POST MARKET | DIN 02195992 |
| SUPRAX | 400 MG | TABLET | AVENTIS PHARMA INC | CANCELLED POST MARKET | DIN 02195984 |
| SUPRAX - TAB 200MG | 200 MG | TABLET | RHONE-POULENC RORER CANADA INC. | CANCELLED POST MARKET | DIN 02195976 |
Who else supplies CEFIXIME worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CEFIXIME appears in 4714 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.